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ABSTRACT
Objectives: To analyse developments (and their
causes) in the number and proportion of clinical trials
that were registered in different parts of the world after
the International Committee of Medical Journal Editors
(ICMJE) announced in 2004 that it would require
registration of clinical trials as a condition for
publication.
Setting: The International Clinical Trials Registry
Platform (ICTRP).
Design: The ICTRP database was searched for all
clinical trials that were registered up to 31 December
2013.
Results: The ICTRP database contained data on
186 523 interventional clinical trials. The annual number
of registered clinical trials increased from 3294 in 2004
to 23 384 in 2013. Relative to the number of clinical trial
research publications, the global number of registered
clinical trials increased fivefold between 2004 and 2013,
rising particularly strongly between 2004 and 2005. In
certain regions, especially Asia, the annual number of
registered trials increased more gradually and continued
to increase up to 2013. In India and Japan, two
countries with marked but more gradual increases,
these increases only happened after several local
measures were implemented that encouraged and
enforced registration. In most regions, there was a trend
toward trials being registered at local registries.
Conclusions: Clinical trial registration has greatly
improved transparency in clinical trial research.
However, these improvements have not taken place
equally in all parts of the world. Achieving compliance
with registration requires a coalescence of global and
local measures, and remains a key challenge in many
countries. Poor quality of registered trial data and the
inaccessibility of trial protocols, results and participant-
level data further undermine the potential benefits of
clinical trial registration. National and regional registries
and the ICTRP have played a leading role in achieving
the successes of trial registration to date and should be
supported in addressing these challenges in the future.
INTRODUCTION
More than half of all clinical trials are never
published and outcomes of clinical trials are
frequently selectively reported.1 Besides
resulting in a waste of resources, this has led
to a situation in which clinical decision-
making is based on biased evidence and in
which patients participate in research that is
never used.2 3 To help increase the ethical
and scientiﬁc value of clinical trial research,
calls for registration of all clinical trials
before the start of recruitment of partici-
pants increased in the 1990s and 2000s.
These calls received broad support, includ-
ing from the WHO4 and from the
International Committee of Medical Journal
Editors (ICMJE) who announced in
September 2004 that starting from July 2005,
Strengths and limitations of this study
▪ To show how global clinical trial registration has
developed globally from 2004 to 2013, this
study analysed the countries of recruitment in
186 523 clinical trials that were registered at 16
clinical trial registries around the world and
provide data to the WHO’s International Clinical
Trials Registry Platform (ICTRP).
▪ By analysing differences in trends in clinical trial
registration between countries and regions, the
study shows that increases in trial registration
have had different trajectories in different parts
of the world, and that a coalescence of global
and local measures is needed to increase the
proportion of trials that is registered in countries.
▪ Reporting on other information of interest
besides trials’ countries of recruitment (eg,
health problems or interventions studied) was
not possible because most data fields in the data
set did not consist of standardised categories.
▪ In the absence of data on actual numbers of
trials that were conducted during this period (we
analysed trials that were registered), this study
sheds light on developments in the proportion of
trials registered by comparing developments in
numbers of registered trials to developments in
annual numbers of publications about clinical
trial research and various countries’ expenditures
on health research.
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all clinical trials must be registered at a clinical trial
registry to be eligible for publication.5 More recently,
the AllTrials campaign has drawn attention to the need
for greater transparency on clinical trials’ methods and
results.6
To show how clinical trial registration has developed
since the ICMJE’s announcement that all trials must be
registered, we provide an analysis in this article of how
many clinical trials have been registered in different
parts of the world up to 2013. By drawing comparisons
to numbers of published articles on clinical trial
research and to countries’ expenditures on health
research, we shed light on how the proportion of clinical
trials that is registered has changed. By studying develop-
ments in the number of registered clinical trials, differ-
ences in those developments between regions and
countries, and differences in the events that have driven
registration, we also provide insight into the measures
that are needed to achieve improved compliance with
trial registration. Finally, we discuss the main challenges
that remain and lie ahead in achieving the goal of full
accessibility to information on all clinical trials’ methods
and results.
METHODS
We searched the database of the International Clinical
Trials Registry Platform (ICTRP) on 8 February 2014 for
all studies that were registered up to 31 December 2013.
The registered records of these studies were downloaded
to Excel. For studies that were registered in more than
one registry (‘duplicate’ registration), only the record
with the earliest registration date was included (all
ICTRP data that are publicly available are automatically
‘deduplicated’, meaning that duplicate records of trials
that have been registered at more than one registry have
been removed). Of the studies that we found, we
excluded all observational studies on the basis of entries
in the ‘Study Type’ ﬁeld.
About the data
The ICTRP was established at the WHO in 2006 to
bring together data on trials registered in national and
regional registries around the world, thus providing one
single point of access to all registered clinical trials glo-
bally.7 When this study was conducted, there were 16
national and regional clinical trial registries in Africa,
Asia, Europe, Latin America and the Caribbean,
Northern America and Oceania that provided data on
registered clinical trials to the ICTRP. For each trial,
information is publicly available in the registered record
on a range of data items that differ per registry, but
contain at least the items in the WHO Trial Registration
Data Set (box 1).8
Analyses
To analyse how clinical trial registration has developed
around the world between 2004 and 2013, we conducted
analyses of: (1) developments in clinical trial registration
globally; (2) developments at each of the 16 registries
where clinical trials were registered; (3) developments in
trial registration in different parts of the world; (4)
changes in annual numbers of registered trials for a
select number of countries as compared to their annual
health research expenditures; (5) developments in clin-
ical trial registration in Japan and India; (6) additional
characteristics of trials, such as their study phase and
target sample size.
1. Developments in clinical trial registration globally
We assessed how many clinical trials were registered
each year to develop insight into trends in the number
of registered clinical trials globally, from 1994 (the earli-
est year of registration of a trial at one of the registries
included in the ICTRP database) to 2013. To shed light
on developments in the proportion of trials registered
each year, ideally we would have compared these
numbers to the actual number of clinical trials con-
ducted each year. However, this was not possible, since
data on the actual number of clinical trials that are con-
ducted are not available. Therefore, we also assessed the
annual number of published articles resulting from clin-
ical trial research, under the assumption that if the
number of clinical trials that were registered increased
relative to the number of publications, the proportion of
trials that were registered may have increased. To do so,
we searched PubMed, on 6 January 2015, using a search
algorithm for the year of publication9 and a search ﬁlter
for clinical trial research (clinical trial [pt]) (corrected
for sensitivity and precision).10 Finally, to shed light on
Box 1 The WHO Trial Registration Data Set (TRDS)
(V.1.2.1)
The 20-item WHO Trial Registration Data Set (TRDS) outlines the
minimum amount of information about a trial that must appear in
a register for a given trial to be considered fully registered:8
1. Primary Registry and Trial Identifying Number
2. Date of Registration in Primary Registry
3. Secondary Identifying Numbers
4. Source(s) of Monetary or Material Support
5. Primary Sponsor
6. Secondary Sponsor(s)
7. Contact for Public Queries
8. Contact for Scientific Queries
9. Public Title
10. Scientific Title
11. Countries of Recruitment
12. Health Condition(s) or Problem(s) Studied
13. Intervention(s)
14. Key Inclusion and Exclusion Criteria
15. Study Type
16. Date of First Enrolment
17. Target Sample Size
18. Recruitment Status
19. Primary Outcome(s)
20. Key Secondary Outcomes
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the signiﬁcance of retrospective registration, we mapped
all trials both by year of registration and by year of ﬁrst
enrolment.
2. Developments at the 16 clinical trial registries that provide
data to the ICTRP
We assessed how many clinical trials were registered
each year at each of the 16 clinical trial registries that
provided data to the ICTRP, for the period 2005–2013
(we chose this period because trials from before 2005
were only registered sporadically). For this analysis, we
did not use our own data set as the ICTRP data that are
publicly available are ‘deduplicated’.11 We collected data
on numbers of interventional, non-deduplicated regis-
tered trials from the websites of the registries, and con-
tacted the 16 registries and the ICTRP to ask for this
information when it was not available online.
We also assessed at which registries trials were regis-
tered for each major geographical region of the world
separately. As only our deduplicated data set contained
information on a trial’s country of recruitment, we used
this data set for the latter analysis.
3. Developments in trial registration in different regions of
the world
We assessed how many clinical trials were registered for
recruitment annually in various regions of the world. An
algorithm was developed to extract the countries of
recruitment from the country of recruitment ﬁeld for
each registered record in the ICTRP data set. Following
this, the trials’ countries of recruitment were classiﬁed
using the World Bank income group classiﬁcation
(February 2014 update) and the United Nations
Statistics Division classiﬁcation for geographical regions
(downloaded on 23 July 2014). If a trial recruited in
multiple regions, it was counted multiple times.
4. Comparison of registered trials with countries’
expenditures on health research
To be able to provide an insight into developments in
the proportion of trials that were registered in various
countries, we compared the annual number of trials
registered for recruitment in these countries to the
countries’ combined public and private expenditures on
health research (under the assumption that if the
number of trials registered increased relative to coun-
tries’ health research expenditures, the proportion of
trials that was registered may have increased). Data on
countries’ public and private health research expendi-
tures combined were derived from publications by
Chakma et al12 and Young et al,13 14 and were available
from 2007 to 2012 for Australia, Canada, China, Europe,
India, Japan, South Korea and the USA.
5. Case studies of India and Japan
Since the comparison of the annual number of trials
registered for recruitment in the countries listed above
to these countries’ health research expenditures showed
especially marked increases for India and Japan (see
Results, section 4), developments in clinical trial registra-
tion in India and Japan were analysed in more detail to
understand what drove the increases in numbers of clin-
ical trials registered in these countries. For trials that
were registered for recruitment in these countries, we
determined at which clinical trial registries these trials
were registered. We also collected information on key
events that may have driven clinical trial registration in
these countries.
6. Additional characteristics of trials
To understand more about additional characteristics of
the trials in our data set and to shed light on what types
of trials were registered between 2004 and 2013, we also
collected information on trials’ study phase and target
sample size in addition to the information that we col-
lected on trials’ countries of recruitment, and calculated
aggregates for the period 2005–2013 (we chose this
period because trials from before 2005 were only regis-
tered sporadically). Collecting information on other
characteristics of interest was not possible for our data
set because most data ﬁelds in the ICTRP data set do
not consist of standardised categories; these are free-text.
Several studies have been conducted on samples of the
ICTRP data set in the past that have shed light on trials’
characteristics in terms of primary sponsor type, inter-
vention type, study design, disease or other health
problem under study and age and sex of study partici-
pants.15 16 In addition, some individual registries that
provide data to the ICTRP do use standardised categor-
ies and provide opportunity for automated analyses of
such characteristics.17 18
RESULTS
Our search of the ICTRP database resulted in 223 181
studies, of which 36 658 studies were excluded because
these were observational. In total, 186 523 interventional
clinical trials with a registration date up to 31 December
2013 were included.
1. Trends in global clinical trial registration up to 2013
Figure 1 shows how many trials were registered each
year globally from 1998 to 2013, and mentions several
key events in clinical trial registration. The annual
number of registered clinical trials increased substan-
tially between 2004 and 2013, particularly between 2004
and 2005: from 3294 in 2004, to 15 752 in 2005, to
23 384 in 2013. This entails a sevenfold increase
between 2004 and 2013, and a ﬁvefold increase relative
to the number of clinical trial publications. From 1999
to 2004, the ratio of the number of registered trials to
the number of publications about clinical trials was 0.10,
while from 2005 to 2013, this ratio was 0.61 (the ratios
were 0.12 in 2004 and 0.53 in 2005).
Figure 1 also maps the numbers of registered clinical
trials by year of ﬁrst enrolment. By comparing these with
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the numbers of registered clinical trials by registration
year, it becomes clear that the peak of trials registered in
2005 consisted partially of a ‘catch-up’ of trials with
dates of ﬁrst enrolment in earlier years. Moreover, this
comparison shows that there is a gap of increasing size
between these two time lines from 2010 to 2013. This
gap exists because many trials are registered retrospect-
ively (24.9% of all trials registered in 2013 reported a
date of ﬁrst enrolment in 2012 or in an earlier year;
12.2% in 2012, 5.2% in 2011, 2.8% in 2010, 1.7% in
2009, 1% in 2008 and 2% in 2007 or earlier). This
means that an increasing proportion of trials with dates
of ﬁrst enrolment in these years had most likely not
been registered yet on 31 December 2013.
2. Registered trials at the 16 clinical trial registries that
provide data to the ICTRP
Figure 2 shows at which clinical trial registries clinical
trials were registered from 2005 to 2013. ClinicalTrials.
gov was the largest registry, with 128 976 registered inter-
ventional trials up to 31 December 2013. However, trials
were increasingly registered at other registries from 2005
to 2013. This becomes clear particularly when the regis-
tries are mapped for each major world region separately
(see online supplementary ﬁle 1). This analysis shows
that in most regions, trials were increasingly registered at
local registries, except in Europe, where rules and regu-
lations around clinical trials were criticised for being
excessively bureaucratic during this time period.19
3. Developments in trial registration in different regions of
the world
Information on trials’ country(ies) or region(s) of recruit-
ment was available for 179 724 trials. Figure 3 provides an
overview of how many trials were registered every year for
participant recruitment in different parts of the world.
From 1999 to 2004, the ﬁgure shows small increases in the
annual numbers of trials registered for recruitment in
Northern America and in Europe, corresponding to
increases in numbers of trials registered at ClinicalTrials.
gov, the International Standard Randomised Controlled
Trial Number Register (ISRCTN), and the EU Clinical
Trials Register (EU-CTR) (see ﬁgure 2). In 2005, the year
that trial registration became a prerequisite for publication
according to ICMJE guidelines, annual numbers of regis-
tered trials showed marked increases in all regions, par-
ticularly in Northern America and in Europe. In other
regions, particularly Asia, the annual number of regis-
tered clinical trials increased more gradually and contin-
ued to increase up to 2013. Numbers of registered
Figure 1 Annual numbers of registered clinical trials on the International Clinical Trials Registry Platform (ICTRP) and annual
numbers of publications about clinical trials on PubMed from 1998 to 2013. The first trials in the ICTRP database were registered
in 1994; 15 trials registered from 1994 to 1997 are not shown in the figure (all registered at the Australian New Zealand Clinical
Trials Registry (ANZCTR)). CONSORT, Consolidated Standards of Reporting Trials; EMA, European Medicines Agency; FDA,
Food and Drug Administration; FDAAA, Amendments Act; ICMJE, International Committee of Medical Journal Editors; ICTRP,
International Clinical Trials Registry Platform; ISRCTN, International Standard Randomised Controlled Trial Number Register.
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Figure 2 Proportion of clinical trials on the International Clinical Trials Registry Platform (ICTRP) that is registered at each of the
16 national and regional registries that provide data to the ICTRP. Figure (A) shows the proportion of trials on ClinicalTrials.gov
versus the 15 other registries. Figure (B) shows the proportion of trials on all registries except ClinicalTrials.gov. Legend is
ordered by numbers of registered trials in 2013. In (B), registries with less than 500 registered clinical trials in 2013 were
combined into ‘Other’ for legibility. The earliest registration date of a trial for each of the 16 national or regional registries that
provided data to the ICTRP was in the following years: 1994, Australian New Zealand Clinical Trials Registry (ANZCTR); 1999,
ClinicalTrials.gov; 2000, International Standard Randomised Controlled Trial Number Register (ISRCTN); 2004, EU Clinical Trials
Register (EU-CTR); 2004, The Netherlands National Trial Register (NTR); 2005, Japan Primary Registries Network ( JPRN);
2006, Chinese Clinical Trial Registry (ChiCTR); 2007, Clinical Trials Registry—India (CTRI); 2007, Sri Lanka Clinical Trials
Registry (SLCTR); 2008, Cuban Public Registry of Clinical Trials (RPCEC); 2008, German Clinical Trials Register (DRKS); 2008,
Iranian Registry of Clinical Trials (IRCT); 2008, Pan African Clinical Trial Registry (PACTR); 2010, Clinical Research Information
Service (CRiS), Republic of Korea; 2010, Thai Clinical Trials Registry (TCTR); 2011, Brazilian Clinical Trials Registry (ReBEC).
Totals do not add up to 100% because trials can be registered at more than one registry. For the same reason, the ‘Total
non-ClinicalTrials.gov’ category in (A) and the ‘Other’ category in (B) may be slight overestimations. For CTRI and JPRN precise
data on the annual number of registered interventional clinical trials could not be acquired; data were approximated from the
overall number of studies (interventional and observational) on these registries’ websites and the distribution of interventional and
observational trials from these registries on the ICTRP.
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clinical trials were lowest in Africa, and in Latin America
and the Caribbean. Finally, registration appears to show a
second peak in Northern America in 2008.
4. A more detailed look at Asia: numbers of registered
trials versus countries’ expenditures on health research
Given the marked, yet gradual increase in numbers of
registered clinical trials between 2005 and 2013 in Asia,
we took a closer look at developments in clinical trial
registrations in this region. Was a gradually increasing
proportion of trials registered in this region? Or, given
the large increases in the annual health research expen-
ditures of several Asian countries in recent years, was
simply more money spent on health research, with
larger numbers of clinical trials being the conducted as
a result?12 13
To answer these questions, we compared increases in
the numbers of clinical trials registered for recruitment
in several Asian countries to these countries’ annual
health research expenditures between 2007 and 2012.
Figure 3 Annual numbers of
clinical trials on the International
Clinical Trials Registry Platform
(ICTRP) registered for recruitment
in country income groups (A) and
geographical regions (B) from
1998 to 2013. Legend is ordered
by numbers of registered trials in
2013. Numbers for further
regional disaggregation for the
year 2013 do not add up to
regional totals because trials
were regularly registered for
recruitment in multiple regions.
Information on countries or
regions of recruitment was
available for 179 724
interventional trials. A total of 113
trials only specified a region of
recruitment (eg, Asia) and not a
country of recruitment, and were
not included for the income group
analysis.
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We did the same for Australia, Canada, Europe and the
USA. Since these analyses took 2007 as a starting point,
they provide insight speciﬁcally at increases in registra-
tion that occurred after the initial global registration
peak of 2005. As ﬁgure 3 shows, most increases in Asia
occurred after this initial peak, but increases in
Northern America and Europe mostly occurred before
this time period; so in these latter two we would expect
little growth between 2007 and 2012.
The results of this analysis are presented in table 1.
Indeed, the USA and Europe showed only marginal
increases in annual numbers of registered trials from
2007 to 2012, in absolute terms and relative to their
annual expenditures on health research. Compared to
increases in the USA and Europe, increases in Canada
and Australia were larger between 2007 and 2012. China
and South Korea showed substantial increases in annual
numbers of registered trials in the same period, but also
saw large increases in their national health research
expenditures. Finally, India and Japan saw large
increases in annual numbers of registered clinical trials,
in absolute terms and relative to the countries’ health
research expenditures. The next section will look in
more detail at what happened in these two countries
that might have resulted in an increasing proportion of
trials being registered.
5. A more detailed look at India and Japan
Figure 4 provides more insight into developments in
clinical trial registration in India and Japan. In both
countries, the annual number of registered trials
increased somewhat in 2005 after the ICMJE’s statement
on trial registration, but not as prominently as in Europe
or Northern America. The annual number of trials regis-
tered only really gained momentum in these countries
after several local measures were taken to enforce and
encourage clinical trial registration. Notably, a large
majority of the trials in India and Japan were registered
at the countries’ national trial registries.
6. Trial characteristics
Besides looking at developments in clinical trial registra-
tion in different regions of the world, we also analysed
the characteristics of the trials that were registered.
Study phase and target sample size were assessed for all
trials on the ICTRP that were registered between 2005
and 2013 (table 2). For 53.3% of these trials, the study
phase was not available. When it was available, the distri-
bution of trials was quite evenly spread across phase I
trials (9.3%), phase II trials (13%), phase III trials
(10.1%) and phase IV trials (8.7%).
The target sample size was not available for 6.9% of
trials. For the remainder, the median target sample size
was 74 (IQR: 34–200). Most trials were small and
recruited between 10 and 100 participants (50.5%).
Table 2 also presents aggregate data for the period
2005–2013 for the registries at which the trials were regis-
tered and for trials’ regions of recruitment. To provide a
recent overview of where registered clinical trials recruited
participants globally, we also analysed the regions of
recruitment for trials registered in 2013. In this year,
73.8% of trials with information on the country of recruit-
ment were registered for recruitment in high- income
countries, 20.2% in upper middle-income countries, 6%
in lower middle-income countries and 0.8% in low-income
countries. For the same year, 39% of trials were registered
for recruitment in Asia, 28.1% in Northern America,
26.6% in Europe, 6% in Oceania, 3.6% in Latin America
and the Caribbean and 2.4% in Africa (ﬁgure 3).
DISCUSSION
Increasing utilisation of registered clinical trial data
Patients, healthcare workers, researchers and policy-
makers are increasingly making use of the information
that is collected and made publicly available by clinical
trial registries.7 15 Registration has brought improved
access to information about clinical trials for patients,
healthcare workers and researchers, particularly because
all registered trials are now accessible through one
global portal (the ICTRP search portal).11 Trial registra-
tion has also made important contributions to increasing
the scientiﬁc value of clinical trial research. A key
example of this is that trial registration is already
helping to address the pertinent problems of publication
Table 1 Proportional increases in the annual number of
registered clinical trials between 2007 and 2012 relative to
proportional increases in national health research
expenditures in eight selected countries
Proportional
increase in
number of
registered
clinical trials
2007–2012
(%)
Proportional
increase in
national
health
research
expenditures
2007–2012
(%)
Increase in
number of
registered
trials 2007–
2012/
increase
in countries’
health
research
expenditures
2007–2012
(%)
Japan 474 111 428
India 367 146 251
Canada 142 87 164
South
Korea
344 213 162
Australia 167 111 151
China 407 321 127
USA 112 97 115
Europe 109 98 112
For all regions, except Europe, data were recalculated from data
from Chakma et al12 using methods by Young et al.13 14 For
Europe, this recalculation could not be performed because
country-specific data were not available, and so we used the
original data from Chakma et al12 instead.
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bias and selective reporting bias by allowing reviewers to
ﬁnd non-published trials and non-published outcomes
when conducting systematic reviews.20 21
Another useful application of clinical trial registration
is that registered clinical trial data are increasingly being
used to shed light on what clinical trial research is being
conducted, where it is being conducted, by whom and
how.16 22 Such insights into the global clinical trial enter-
prise can help in targeting the research that has the
greatest potential public health beneﬁt, and the ICTRP
will likely constitute a useful data source for the recently
established Global Observatory on Health Research and
Development (R&D) (a new initiative at WHO that will
aim to provide insight into what health R&D is being
conducted globally).22 23 For example, this study showed
that in recent years there were more clinical trials regis-
tered for recruitment in Asia than in Europe or the
USA. Other studies have made clear that registered clin-
ical trials are dominated by research into non-
communicable diseases (80%), less than 20% of trials
recruit children, more than 60% are sponsored by uni-
versities or hospitals and more than 50% investigate
drugs.15 16 24
The use of registered clinical trial data for these pur-
poses is valuable; however, it also raises questions. How
many trials and what proportion of trials are registered
at this moment? Also, how much information, and of
what quality, is available about these trials?
Increases in the number and proportion of trials that are
registered
This study shows that the number of trials that was regis-
tered every year increased from 3294 in 2004, to 15 752
in 2005, to 23 384 in 2013. Moreover, the proportion of
trials registered each year globally appears to have
increased substantially between 2004 and 2013, particu-
larly between 2004 and 2005. In 2013, the number of
clinical trials that was registered was ﬁvefold that of what
Figure 4 Developments in
clinical trial registration in India
and Japan. Legend is ordered by
numbers of registered trials in
2013. Details on events related to
clinical trial registration were
mostly derived from Pandey
et al,46 Shiokawa80 and Tang
et al.48 Data are from our
deduplicated data set that was
downloaded from the ICTRP. A
proportion (15.6%) of registered
records of trials was excluded
from this data set because the
corresponding trials were
registered at more than one
registry. Thus, numbers of
registered records for individual
registries are in reality somewhat
higher than in the graph. The
non-deduplicated number of
interventional trials registered for
recruitment in India in 2013 at
ClinicalTrials.gov, for example,
was 199 (in graph 159) and for
recruitment in Japan in 2013 was
363 (282 in graph) (numbers from
ClinicalTrials.gov website). JPMA,
Japanese Pharmaceutical
Manufacturers Association;
JPRN, Japan Primary Registries
Network; MHLW, the Ministry of
Health, Labour and Welfare;
ICMJE, International Committee
of Medical Journal Editors.
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Table 2 Characteristics of all interventional clinical trials on the International Clinical Trials Registry Platform (ICTRP) registered
from 2005 to 2013 (N=173 532)
Category
Number of trials
registered from 2005–2013
Percentage of all clinical
trials registered from
2005–2013 (%)
Region (income groups)*
High-income countries 143 137 82.5
Upper middle-income countries 24 937 14.4
Lower middle-income countries 8229 4.7
Low-income countries 1433 0.8
Not specified 6319 3.6
Region (geographical)*
Northern America 61 170 35.2
Europe 61 115 35.2
Asia 43 364 25.0
Oceania 10 432 6.0
Latin America and the Caribbean 7476 4.3
Africa 3916 2.3
Not specified 6211 3.6
Registry name*,†
ClinicalTrials.gov 119 046 68.6
EU-CTR 21 268 12.3
JPRN 11 251 6.5
ISRCTN 9174 5.3
ANZCTR 7900 4.6
IRCT 5266 3.0
CTRI 3731 2.2
NTR 3481 2.0
ChiCTR 2924 1.7
DRKS 1431 0.8
CRiS 679 0.4
PACTR 289 0.2
ReBEC 272 0.2
RPCEC 169 0.1
SLCTR 116 0.1
TCTR 95 0.1
Study phase
0 926 0.5
I 16 101 9.3
I and II 5478 3.2
II 22 616 13.0
II and III 3062 1.8
III 17 469 10.1
III and IV 155 0.1
IV 15 180 8.7
Not specified 92 545 53.3
Target sample size
1–9 4534 2.6
10–99 87 653 50.5
100–999 61 938 35.7
1000–9999 6671 3.8
10 000 –99 999 622 0.4
100 000 or more 77 0.0
Not specified 12 037 6.9
Total per category 173 532 100
*Overlap was possible, total in this category was greater than 100%. Trials regularly recruit participants in multiple regions, and trials are often
registered at more than one registry.
†Registry acronyms stand for: EU Clinical Trials Register (EU-CTR), Japan Primary Registries Network ( JPRN), International Standard
Randomized Controlled Trial Number Register (ISRCTN), Australian New Zealand Clinical Trials Registry (ANZCTR), Iranian Registry of
Clinical Trials (IRCT), The Netherlands National Trial Register (NTR), Clinical Trials Registry—India (CTRI), Chinese Clinical Trial Register
(ChiCTR), German Clinical Trials Register (DRKS), Clinical Research Information Service (CRiS) Republic of Korea, Brazilian Clinical Trials
Registry (ReBEC), Pan African Clinical Trial Registry (PACTR), Cuban Public Registry of Clinical Trials (RPCEC), Sri Lanka Clinical Trials
Registry (SLCTR), and Thai Clinical Trials Registry (TCTR). For CTRI and JPRN precise data on the annual number of registered
interventional clinical trials could not be acquired; data were approximated from the overall number of studies (interventional and
observational) on these registries’ websites and the distribution of interventional and observational trials from these registries on the ICTRP.
Viergever RF, Li K. BMJ Open 2015;5:e008932. doi:10.1136/bmjopen-2015-008932 9
Open Access
it was in 2004, relative to the number of publications
about clinical trial research.
Other studies conﬁrm that the proportion of trials
that are registered has shown an upward trend, and
show that at least 60% of all trials that were published
were also registered in recent years (box 2).25 26
However, the proportion of published trials that is regis-
tered varies considerably as per type of research, per
country and per journal in which the research is pub-
lished (box 2).25–36 Our study too shows that develop-
ments in the number and proportion of trials that are
registered have not taken place equally in all parts of the
world. In Northern America and Europe, for example,
increases in trial registration peaked in 2005, the year
after the statement by the ICMJE on trial registration.
However, in other regions, particularly Asia, trial registra-
tion developed more gradually. By looking in more
detail at several Asian countries, our study shows that the
annual number of registered clinical trials continued to
increase substantially in China, South Korea, India and
Japan after the initial global registration peak in 2005.
In China and South Korea, these increases were
accompanied by substantial increases in the countries’
expenditures on health research. This may suggest that
while the number of annually registered trials increased,
the proportion of trials registered may not have
increased as much (however, caution is warranted in
drawing such conclusions; we used countries’ expendi-
tures on health research as a proxy for the number of
trials being conducted in a country, but these two are
not necessarily linearly correlated). India and Japan saw
strong increases in numbers of registered clinical trials
in absolute numbers and relative to their annual expen-
ditures on health research, suggesting strong increases
in the proportion of trials that was registered. This is
why we studied developments in trial registration in
these two countries in more detail.
Global and local reasons for good and poor compliance
with registration in different regions
Global reasons
There have been several global measures between 2004
and 2013 that have helped to provide an impetus for
clinical trial registration. Examples include: codes of
research practice, such as the SPIRIT and CONSORT
statements that have been revised to recommend the
admission of trial registration details to both clinical trial
protocols and reports;37 38 statements from professional
organisations supporting trial registration, such as the
declaration of Helsinki;39 and statements by pharmaceut-
ical industry associations supporting trial registration.40
A particularly inﬂuential global measure was the
ICMJE’s announcement that it would require trial regis-
tration as a condition for publication in 2004, which led
to a substantial increase in the number of trials regis-
tered in 2005.41
These measures have made an important contribution
to stimulating trial registration, but have not been a
panacea. The ICMJE’s policy, for example, only impacts
a subsection of all trials: more than 50% of all trials are
never published1 and some trials may not even be con-
ducted with the goal of publication. The ICMJE’s recom-
mendations have also lacked widespread
implementation: the percentage of English-language
journals that actually requires or encourages trial regis-
tration is 30%, and even these journals often do little to
check compliance with registration.42 This proportion is
likely to be lower for non-English language journals,
since registration rates are signiﬁcantly lower in these
journals.28 Moreover, this study shows that while the
number of trials registered for recruitment in Europe
and Northern America rose steeply after the ICMJE’s
announcement, increases in other regions were more
gradual. In Asia, particularly, clinical trial registration
only really gained momentum after a range of local
measures were implemented (in Europe and the USA,
many such measures had already been implemented at
the time of the ICMJE’s announcement).
Box 2 How many published clinical trials are registered?
The proportion of all published clinical trials that is registered
varies considerably per research area and per journal. This pro-
portion has been shown to be: approximately 30% for trials pub-
lished in physiotherapy journals,28 29 yet 75% for trials that are
published in the top 10% of these journals;28 21% for trials that
are published in top psychosomatic and behavioural health jour-
nals;30 24% for randomised controlled trials (RCTs) in kidney
transplantation;31 59.4% for trials published in urology-related
journals, but 71% if the journal mentioned trial registration in its
author requirements;32 and 87% for RCTs in the 10 highest
ranked surgery journals (by impact factor) that also required trial
registration.33
Registration rates also vary per country: among USA-sponsored
trials advertised to Russian patients and physicians one-third of
the trials on ClinicalTrials.gov did not disclose a Russian location
of recruitment, and only 16.9% of publications of RCTs with a
Latin American first author reported that the trial was
registered.34 35
Analysis of RCTs across all research areas and countries shows
that 37% of publications of trials in 2007 reported that the trial
was registered.26 In 2010, 55% did so, while additional searching
showed that at least 61% of the trials was registered (64% in
ICMJE journals and 52% in non-ICMJE journals).25 This trend is
in line with the increasing numbers of registered trials observed
in this study, and with other authors who have reported that
registration rates improved over time for their
subsamples.29 31 32 36
Finally, it should be noted that the proportion of all trials that is
registered—not just the proportion of published trials—is likely
lower than the 61% discussed above, assuming that investigators’
reasons for not publishing a trial may overlap with their reasons
for not registering a trial (potentially leading to a smaller propor-
tion of trials that is registered among unpublished trials).
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Local reasons
Arguably, the most important local measure that can be
taken is to make registration mandatory by law.43
Although our analysis was not developed to provide evi-
dence to this end, there may be some indications of the
effects of legislation in our results: registration appears
to show a peak in Northern America in 2008, 1 year
after implementation of legislation that expanded the
scope of trial registration in the USA;44 and in Canada
and Australia, countries that had no legislation on trial
registration, when the ICMJE issued their statement on
trial registration in 2004, the number of registered trials
increased more slowly than it did in Europe and the
USA, where legislation on trial registration already
existed at the time.
In an increasing number of countries laws that
mandate trial registration exist, including: Argentina,
Brazil, Canada (since 2014), EU member states, India,
Israel, South Africa and the USA.43 45 However, in most
countries, particularly in low- and middle-income coun-
tries, such legislation remains absent. Moreover, even in
countries with legislation on trial registration, the law
tends to not cover all clinical trials (excluding, eg, non-
medicine or device trials and phase I trials),15 44 thus
explaining the low registration rates that are found for
clinical trials that fall outside these parameters, such as
physiotherapy trials or behavioural trials (box 2).28 30
Besides legislation, there are several other local mea-
sures that can have a signiﬁcant impact on the propor-
tion of trials that are registered in a country. Japan, for
instance, a country that lacks a comprehensive law on
trial registration, still saw substantial increases in
numbers of registered trials in recent years. One particu-
larly important measure has been the establishment of
national, local-language registries.7 The number of
national and regional registries that provide data to the
ICTRP has risen from 3 to 16 since the ICTRP’s estab-
lishment and in most regions, there has been a trend
towards trials being registered at such registries (ﬁgure
4; online supplementary ﬁle 1). Besides offering oppor-
tunity for registration of trials in the national language,
these local registries can galvanise the establishment of
other enforcement measures by advocating for the estab-
lishment of local legislation and policies on
registration.7 46
Other local measures that have helped to stimulate
trial registration include: enforcement of registration by
funders, ethics committees and local journal
editors;46 47 national policies and ethical guidelines that
encourage trial registration;48 and self-regulation by uni-
versities 45 and the pharmaceutical industry.40 Japan and
India provide good examples of how clinical trial regis-
tration increased when a range of these measures were
implemented (ﬁgure 4). A key example also comes from
the UK, where registration was recently made a condi-
tion for ethics approval for all clinical trials.49 Chalmers’
follow-up suggestion to automatically generate trial regis-
tration entries from applications to the UK’s integrated
research application system appears particularly prac-
tical.49 Another example comes from the US National
Institutes of Health (NIH) that have recently issued a
draft policy for public comment on clinical trial registra-
tion.44 Importantly, both the UK ethics initiative and the
NIH initiative supplement existing EU and USA legisla-
tion by requiring registration for any clinical trial,
regardless of the type of intervention and study phase.
The problem is that many of these successful measures
have lacked widespread implementation. In most coun-
tries, particularly in low- and middle-income countries,
the absence of legislation on registration, of a national
registry and of policies on registration by ethics commit-
tees, funders and journal editors leaves much room for
investigators to not register their trials. The low registra-
tion rates that have been found for trials in Latin
American and Caribbean countries, for example, may
well be explained by the relative absence of such devel-
opments in these countries.34 The knowledge needed to
redress the lack of compliance in these countries exists;
implementation of local measures that have proven
effective and improved trial registration rates elsewhere
would be likely to greatly help improve compliance in
these countries as well.
Other remaining challenges for clinical trial registration
The challenge of lacking compliance is key for clinical
trial registration, but there are several other issues that
will require attention in the future to allow for the bene-
ﬁts of clinical trial registration to be realised, particularly
in the areas of: (1) data quality, (2) (in)accessibility of
protocols, results and participant-level data, and (3)
searchability, data aggregation and linking at the ICTRP
and registries. These are discussed here below.
Data quality
Although the ICMJE has stated that “trial registration
with missing or uninformative ﬁelds for the minimum
data elements is inadequate”,50 many registered records
of clinical trials are currently incomplete, not accurate,
not up-to-date or retrospectively registered.15 51 52 For
example, listed primary outcome measures are often not
speciﬁc enough to allow for the detection of selective
reporting.15 21 41 51
Retrospective registration means that, in contrast with
ICMJE and WHO guidelines, many trials are registered
after they have begun recruiting participants. In this
study, one-quarter of all trials registered in 2013 started
recruitment in an earlier year, but the rate of retrospect-
ive registration in reality is even higher: when we look
per month, instead of per year, 48% of trials registered
in 2012 were registered retrospectively.15 This is a major
problem because when trials are registered retrospect-
ively, we cannot be sure that they were not registered to
favour a particular result.
A key solution to the problem of lacking data quality is
to improve the data recording formats and quality
control measures at registries (there are large variations
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between registries in this regard15). The ICTRP has
attempted to encourage such improvements by publish-
ing the International Standards for Clinical Trial
Registries in 2012.53
(In)accessibility of protocols, results and participant-level
data
This study has focused on exploring developments in
clinical trial registration in different parts of the world;
however, the registration of a trial is just a ﬁrst step. It is
equally important that a trial’s protocol, summary
results, full study report and participant-level data set
can be accessed. However, research has shown that these
are only rarely available.2 Moreover, more than half of
all trials are never published in journals.1 Several coun-
tries, such as the USA, EU, Canada and Japan, as well as
the WHO have implemented measures to redress the
lack of availability of trial results.19 44 54–66 Unfortunately,
as for improving compliance with registration itself,
these local measures have not been widely implemented;
similar measures remain absent in many other countries.
In terms of achieving sharing of participant-level data
sets, less progress has been made.2 67 However, there are
strong signs that sharing of participant-level data sets is
becoming broadly accepted as the new standard in clin-
ical trial transparency and that progress in this area can
be expected in the near future.66 68–73
Searchability, data aggregation and linking at the ICTRP and
registries
The establishment of the ICTRP in 2006 was an import-
ant step forward for clinical trial registration. The
ICTRP has contributed to the development of standards
both for clinical trial registries 53 74 and for the data that
are collected for each trial.8 Most importantly, the
ICTRP has linked data from individual clinical trial regis-
tries and its search portal serves as a single point of
access to all registered clinical trials for patients, health-
care workers, researchers and policymakers.
As the single point of access to all registered clinical
trials, it is important that the ICTRP database is search-
able for individual records, that it provides opportunity
for aggregate analyses, and that it links to the related
trial documents and data mentioned in the previous
section (protocols, summary results, clinical study
reports, publications and participant-level data). There
is potential for improvement in how the ICTRP enables
these functions. First, in terms of searchability, the
ICTRP provides various search functions on its portal,
including an advanced search function and a search
ﬁlter for trials in children. However, improvements to
the ICTRP’s search interface are possible: Glanville
et al75 recently concluded that the ICTRP’s search inter-
face lags behind the interfaces of major bibliographic
databases. Second, providing opportunities for aggregate
analyses is a particular challenge for the ICTRP given
that it combines data from 16 different registries. The
ICTRP has made good progress in this area since it
started, but many of the relevant data ﬁelds are still not
available in standardised, categorised formats. Looking
ahead to the establishment of the Global Observatory
on Health R&D,23 and the role that data from the
ICTRP might play in this Observatory,16 22 it is important
that the ICTRP’s opportunities for aggregate analysis are
improved. Third, as the single point of access to all regis-
tered clinical trials, the ICTRP is well-placed to provide
links to all related documents and data for each clinical
trial, such as protocols, various types of results and
participant-level data, but it currently does not provide
ﬁelds for such links. By making available such links
when they exist, the ICTRP could not only become the
single point of access to all registered clinical trials, but
also for access to all information on each registered trial,
which would signiﬁcantly improve the accessibility of
that information.
Since individual registries are the point of access to
clinical trials for people living in a speciﬁc country or a
region, and often provide data in a local language, it is of
equal importance that registries provide adequate search
functions, aggregate analysis possibilities, and links to
protocols, results and participant-level data. However,
many of the areas in which there is potential for improve-
ment at the ICTRP are also areas for potential improve-
ment for the 16 registries that provide data to the ICTRP.
The search function quality, aggregate analysis possibil-
ities and provision of links vary greatly per registry.15 75 76
Both registries and the ICTRP could learn more from
successful approaches in these areas at other registries.15
Limitations
The ICTRP currently accepts data from 16 national and
regional registries around the world that comply with a
range of quality criteria.74 There are other registries for
clinical trials (eg, for the pharmaceutical industry); so
we may not have captured all registered clinical trials
globally in this study. However, there is broad endorse-
ment for trial registration in WHO-approved registries;
most of the laws that legislate clinical trial registration
and the ICMJE’s registration policy prescribe that trials
must be registered in a registry that provides data to the
ICTRP.50 Therefore, any information missed from regis-
tries that are not included should be limited.
In this study, we aimed to shed light on developments
in the number and the proportion of clinical trials that
were registered from 2004 to 2013. However, a key limita-
tion in conducting this analysis was that for calculating
the proportion of trials that were registered, information
on the denominator for this calculation—the actual
numbers of clinical trials that were conducted—was
missing. To shed light on developments in the propor-
tion of clinical trials that were registered, we compared
annual numbers of registered clinical trials to annual
numbers of publications about clinical trial research and
to countries’ expenditures on health research, under
the assumption that if the number of trials had
increased relative to these proxies, the proportion of
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trials that was registered may also have increased. By
demonstrating the strong increases in numbers of regis-
tered trials relative to these proxies during a short time
period, and by drawing on literature that has also pro-
vided indications of trends towards increasing compli-
ance with registration (box 2), we believe to have made
it plausible that—like the number of clinical trials that
were registered—the proportion of clinical trials that was
registered increased between 2004 and 2013, particularly
between 2004 and 2005.
This study was limited to investigating how the registra-
tion of clinical trials developed between 2004 and 2013 in
different parts of the world and what factors drove those
developments. However, many of the rationales for regis-
tering clinical trials also apply to other types of
research.77 78 Efforts to enforce and encourage registra-
tion of other types of research have progressed much less
than for clinical trial research, but observational studies
can be registered at most clinical trial registries, and a
register for systematic reviews has also been established.79
In our data set, 16% of all studies was observational.
Since there has been much less enforcement of registra-
tion of observational research to date than of clinical trial
research, we excluded these observational studies from
our study, so as to not let these distort our ﬁndings.
CONCLUSION
Clinical trial registration has improved transparency in clin-
ical trial research by increasing access to information on
clinical trials around the world. More than 20 000 clinical
trials are now newly registered every year at 16 national and
regional registries, and healthcare workers, researchers,
patients and policymakers are increasingly beneﬁting from
the advantages offered by clinical trial registration.
However, this study shows that trial registration has not
developed equally in all parts of the world, and that good
compliance with registration requires a coalescence of
global and local measures that enforce and encourage
registration. As local measures are not in place in most
countries, compliance with registration remains a signiﬁ-
cant challenge that continues to undermine the potential
beneﬁts of clinical trial registration. Other important chal-
lenges that remain include substandard quality of data in
registered records of trials, inaccessibility of protocols,
results and participant-level data, and the potential for
improvement in registries’ and the ICTRP’s searching,
aggregating and linking functions. For most of these chal-
lenges, effective solutions are available, but there is lack of
widespread implementation. National and regional regis-
tries around the world and the ICTRP have played a
leading role in the implementation of such solutions in the
past. It is important that they are supported to address the
challenges that remain in the future, so that we can pro-
gress further towards the goal of full accessibility to infor-
mation on all clinical trials’methods and results.
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